Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Marginal Zone Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
In May 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
In May 2025, Incyte Corporation organized a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
In May 2025, Genmab conducted a study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends.
DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies
Marginal Zone Lymphoma Emerging Drugs
Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Marginal Zone Lymphoma Pipeline Report
Coverage- Global
Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Marginal Zone Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
EO2463: Enterome
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
4 Undeniable Factors That Could Push Bitcoin to New All-Time Highs This Summer
Some moments in the market don't need dramatic catalysts; they just quietly build up momentum until something gives. For Bitcoin, (CRYPTO: BTC) the stars are aligning with uncanny precision in ways that are likely to have a stunning result. Four macro forces, each with a history of preceding major rallies in the coin, are once again in play. Here's what's unfolding, and why it might matter more than most investors realize. 1. Surging global liquidity When central banks turn on the liquidity tap and ensure there's more money sloshing around the financial system, that new money generally flows toward riskier assets, such as cryptocurrency, as greater liquidity emboldens investors to take riskier bets. Furthermore, safer asset classes would have already been bid up to the point of being fairly expensive from the perspective of institutional allocators. The global M2 money supply hit roughly $108.4 trillion in April, climbing at a pace last seen right before Bitcoin's 2021 breakout to new highs. The coin's performance tends to lag that liquidity gauge by about one quarter. Liquidity waves eventually peak, but the cash they inject never fully drains from the financial system. If part of that additional base money ends up permanently sequestered in Bitcoin wallets -- as happened after prior monetary easing cycles -- holders will enjoy a higher floor even after central banks commence with new tightening cycles. 2. A weaker dollar When the value of the dollar drops, investors often opt to park their capital in stronger assets that are retaining or increasing in value, like, potentially, Bitcoin. The dollar index is down roughly 10% year to date, its worst six-month slide since 1986. Fund managers are the most underweight to the currency in two decades, per a recent survey conducted by Bank of America. For investors, dollar weakness is more than a near-term tailwind for Bitcoin. A softer greenback often coincides with looser financial conditions abroad, fostering new demand from countries where Bitcoin offers a liquid alternative to depreciating local money. That incremental global bid tends to stick around, because reversing currency weakness usually requires policy shifts that take years to perform. 3. Lower Treasury yields Similar to money supply, interest rates significantly influence Bitcoin's price. As yields on government-backed debt like U.S. Treasury bills drop, and along with it, the cost of borrowing passed on to the financial system, capital needs to flow to riskier assets to secure a return. On that note, benchmark 10-year yields on Treasury bonds have fallen from 4.81% in late January to the low 4% range this week. Every notable Bitcoin surge since 2017 has arrived shortly after real or nominal yields were slipping. That matters for the long haul, because each yield dip trains allocators to view the coin as a portfolio diversifier when bonds offer less income. The habit can persist even after rates rise again, much as gold ownership remained commonplace after real yields recovered in the 1980s. The longer Bitcoin proves able to offset low-yield stretches, the more likely it becomes a fixture in strategic asset mixes rather than a tactical punt. 4. The post-halving supply squeeze Bitcoin's supply situation is also very permissive for the coin to make another run at new all-time highs. The 2024 halving cut miner rewards, decreasing daily issuance to about 450 coins. Demand from institutional investors stemming from their offering of exchange-traded funds (ETFs) holding Bitcoin is running far higher than that flow. Plus, the supply shock math compounds with time. Assuming the price rises even a little, Bitcoin miners will eventually sell even fewer coins to cover their operating costs, and at the same time, new issuance keeps shrinking every four years. That structural throttle on float effectively hands long-term holders an ever-growing share of total outstanding supply, increasing their pricing power, as long as they resist the urge to trade around short-term volatility. The lesson here is that long-term-oriented investors should keep buying Bitcoin, and buckle up, because it has a lot of room to run during this summer and beyond. Should you invest $1,000 in Bitcoin right now? Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
27 minutes ago
- Globe and Mail
MSTR Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy (MSTR) Shareholders of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 21, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') (NASDAQ: MSTR) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategyinvestors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Globe and Mail
43 minutes ago
- Globe and Mail
RGTI, IONQ: 2 ‘Strong Buy' Russell 2000 Stocks Analysts Say You Shouldn't Miss
Small-cap stocks often fly under the radar, but some hold massive upside potential, especially when backed by bullish analyst sentiment. In this context, two standout names from the Russell 2000, Rigetti Computing (RGTI) and IonQ (IONQ) have both earned Strong Buy ratings from Wall Street. Both stocks are part of the quantum computing space and present high-risk, high-reward opportunities for investors. Confident Investing Starts Here: Let's dive into the details. Is RGTI Stock a Good Buy? Rigetti is an early-stage quantum computing company that's gaining attention for its innovative technology and government partnerships. The company's superconducting systems perform ultra-fast operations in just 60–80 nanoseconds, perfect for tasks like AI and financial modeling. With full control over its tech stack, from chip design to cloud access, the company is well-positioned for scalable growth. However, Rigetti's financial story is challenging. In Q1, revenue plunged 52% to $1.47 million, and operating loss came in at $21.6 million. Despite being unprofitable, analysts remain optimistic about its long-term potential in the emerging quantum sector. Rigetti Computing Stock Forecast Last month, Craig-Hallum's five-star-rated analyst Richard Shannon maintained his Buy rating on RGTI stock. Interestingly, all five analysts who rated the stock gave it a Buy, according to TipRanks. Taken together, Rigetti's stock forecast of $15.0 implies an upside of about 32%. Meanwhile, RGTI stock has declined by over 25% year-to-date. See more RGTI analyst ratings Is IonQ a Good Stock to Buy? IonQ, a pure-play quantum computing company using trapped-ion technology, offers its systems through major cloud platforms. It has emerged as a standout in the sector, with its stock soaring over 450% in the past year. The company is ahead of competitors in getting its quantum systems to market, having already sold hardware to Amazon's (AMZN) AWS and Google (GOOGL) Cloud. Its systems feature all-to-all connectivity and boast an industry-leading 99.9% two-qubit gate fidelity, meaning highly accurate results. With a few units already sold and rising demand, more launches are expected soon. Notably, two-qubit gate fidelity measures how accurately a quantum computer links two qubits. IonQ's 99.9% fidelity signals low error rates, key for building reliable, scalable systems. What Is IonQ Forecast for 2025? This month, top analysts from Needham, Benchmark, and Craig-Hallum reiterated their Buy ratings on IONQ stock. Overall, four out of five analysts currently covering the stock have issued Buy recommendations. Meanwhile, the average IonQ shareprice target of $43 suggests an 8.5% upside from current levels. See more IONQ analyst ratings
